Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.83)
# 1,766
Out of 4,876 analysts
80
Total ratings
45.76%
Success rate
7.38%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $22.21 | -0.95% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.60 | +29.31% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $6.50 | +23.08% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $16.39 | +205.06% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $126.71 | +7.33% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $2.66 | +501.50% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $6.18 | +903.24% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $1.50 | +700.00% | 6 | Dec 12, 2023 | |
| SAGE Sage Therapeutics | Initiates: Hold | $21 | $9.28 | +126.29% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $17.23 | +532.62% | 3 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.21 | +561.16% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.25 | +344.44% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $5 | $0.33 | +1,415.15% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $3.78 | +58.73% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.02 | +596.52% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $101.74 | -77.39% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $23.38 | +53.98% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $22.21
Upside: -0.95%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.60
Upside: +29.31%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $6.50
Upside: +23.08%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $16.39
Upside: +205.06%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $126.71
Upside: +7.33%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $2.66
Upside: +501.50%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $6.18
Upside: +903.24%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $1.50
Upside: +700.00%
Sage Therapeutics
Dec 12, 2023
Initiates: Hold
Price Target: $21
Current: $9.28
Upside: +126.29%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $17.23
Upside: +532.62%
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.21
Upside: +561.16%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $2.25
Upside: +344.44%
Nov 11, 2022
Maintains: Buy
Price Target: $7 → $5
Current: $0.33
Upside: +1,415.15%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $3.78
Upside: +58.73%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.02
Upside: +596.52%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $101.74
Upside: -77.39%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $23.38
Upside: +53.98%